Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2018

Filed with the SEC on Sep 12, 2018 and accepted by EDGAR at Sep 12, 2018, 17:23 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-05-01 to 2018-07-31$0us-gaap:Revenues
Research and development3 months2018-05-01 to 2018-07-31$267.8kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-05-01 to 2018-07-31−$1.2mus-gaap:OperatingIncomeLoss
Net income3 months2018-05-01 to 2018-07-31−$1.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-05-01 to 2018-07-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2018-05-01 to 2018-07-311,046,496,430 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2018-05-01 to 2018-07-31−$622.2kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-07-31$1.8mus-gaap:Cash
Current assetsAt period end2018-07-31$2.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-07-31$7.1mus-gaap:Assets
Current liabilitiesAt period end2018-07-31$882.9kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-07-31$882.9kus-gaap:Liabilities
Shareholders' equityAt period end2018-07-31$6.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-18-002721. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.